Abstract
Smoking status is essential to know when taking care of a lung cancer patient. Never-smoking patients account for 15% of lung cancer patients, more often women and adenocarcinoma. Environmental tobacco smoke and occupational exposure could be important risk factors. Lung cancer in never-smoker appears to be a distinct entity from lung cancer in smoker, with specific molecular characteristics such as frequent EGFR mutations. New molecular targets are on investigation, such as EML4-ALK translocation. Treatment of lung cancer in never-smoker is getting different from that of smoker with more efficacy of molecular targeted therapies.
Copyright © 2011. Published by Elsevier Masson SAS.
MeSH terms
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / epidemiology*
-
Adenocarcinoma / genetics*
-
Antineoplastic Agents / therapeutic use
-
Carcinoma, Bronchogenic / drug therapy
-
Carcinoma, Bronchogenic / epidemiology*
-
Carcinoma, Bronchogenic / genetics*
-
Carcinoma, Squamous Cell / drug therapy
-
Carcinoma, Squamous Cell / epidemiology*
-
Carcinoma, Squamous Cell / genetics*
-
Cross-Sectional Studies
-
DNA Mutational Analysis
-
ErbB Receptors / genetics*
-
Gene Expression Profiling
-
Genetic Predisposition to Disease / genetics
-
Humans
-
Incidence
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / epidemiology*
-
Lung Neoplasms / genetics*
-
Molecular Targeted Therapy
-
Oncogene Proteins, Fusion / genetics*
-
Prognosis
-
Risk Factors
-
Smoking / adverse effects*
-
Smoking / epidemiology*
-
Translocation, Genetic / genetics*
Substances
-
Antineoplastic Agents
-
EML4-ALK fusion protein, human
-
Oncogene Proteins, Fusion
-
EGFR protein, human
-
ErbB Receptors